Dr. Liza C. Villaruz
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
40 reported clinical trials
59 drugs studied
About Liza C. Villaruz
Education:
- Obtained MD from the University of Pittsburgh School of Medicine in 2010.
- Completed Residency in Radiation Oncology at the University of Pittsburgh Medical Center in 2015.
- Finished Fellowship in Radiation Oncology at the University of Pittsburgh Cancer Institute in 2016.
Experience:
- Assistant Professor of Radiation Oncology at the University of Pittsburgh School of Medicine.
- Radiation oncologist at the University of Pittsburgh Cancer Institute, with a specialization in breast cancer and gastrointestinal malignancies.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Liza C. Villaruz is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Chemotherapy + Immunotherapy
for Mesothelioma
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
Recruiting1 award Phase 236 criteria
More about Liza C. Villaruz
Clinical Trial Related6 years of experience running clinical trials · Led 40 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Liza C. Villaruz has experience with
- Pembrolizumab
- Carboplatin
- Pemetrexed
- Atezolizumab
- Berzosertib
- Irinotecan Hydrochloride
Breakdown of trials Liza C. Villaruz has run
Lung Cancer
Non-Small Cell Lung Cancer
Parotid Gland Cancer
Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Liza C. Villaruz specialize in?
Is Liza C. Villaruz currently recruiting for clinical trials?
Are there any treatments that Liza C. Villaruz has studied deeply?
What is the best way to schedule an appointment with Liza C. Villaruz?
What is the office address of Liza C. Villaruz?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.